Phathom (PHAT) Q2 2026 earnings review
Milestone Profitability Reached, But Revenue Guidance Trimmed
Phathom reached a critical inflection point in Q2, crossing into operating profitability (excluding stock-based compensation) on the back of $74.3M in record revenue. The strategic pivot to target gastroenterologists is clearly working, driving an 88% YoY surge in VOQUEZNA prescriptions. However, despite the celebratory tone and a 34% YoY drop in cash operating expenses, management quietly lowered its full-year revenue guidance by $15M at the midpoint. This cut suggests a decelerating growth trajectory in the second half of the year, contradicting the narrative of unbridled momentum.
🐂 Bull Case
Management delivered on its promise. Non-GAAP OpEx is stable in the mid-$50M range, while revenue has nearly doubled YoY. Operating leverage is firmly intact.
Total prescriptions hit 325,000, reversing the slight QoQ dip seen in Q1 and proving the GI-focused sales strategy is effectively driving new patient starts and refills.
🐻 Bear Case
Lowering FY26 revenue guidance to $310-$325M during a 'record' quarter is a massive red flag. It implies growth will decelerate or face unexpected headwinds in H2.
Achieving 'non-GAAP operating profitability' masks real cash and dilution costs. With $15.1M in Q2 interest expense and $6.7M in stock comp, the company still posted a $17.6M GAAP net loss.
⚖️ Verdict: ⚪
Neutral. The crossing of the non-GAAP profitability line is a massive de-risking event for the balance sheet, but the lowered revenue guidance caps near-term upside and warrants caution.
Key Themes
Guidance Cut Contradicts Momentum Narrative
CEO Steven Basta claimed Q2 built 'momentum toward realizing the long-term blockbuster potential.' Yet, the company simultaneously lowered FY26 net revenue guidance from $320-$345M to $310-$325M. This specific data point directly contradicts the positive narrative, implying a decelerating growth rate in the second half. If Q2 was a blowout, the guide should have been raised or maintained.
GI Strategy Driving Prescription Acceleration
The pivot to focus on high-writing gastroenterologists is working. Total VOQUEZNA prescriptions hit 325,000 in Q2, up 21% sequentially. This represents accelerating growth compared to the seasonal dip in Q1 (268,000 scripts). Covered scripts outpaced total growth, rising 24% QoQ to 209,000.
Pipeline Expansion: As-Needed (PRN) Dosing
Phathom announced plans to initiate a Phase 3 trial for VOQUEZNA for 'as-needed' (PRN) use in Non-Erosive GERD (NERD) in Q4 2026. This is a critical technological and commercial evolution. Current PPIs take days to reach peak efficacy, making them poor PRN options. VOQUEZNA's rapid onset could unlock a massive new TAM of patients who refuse daily therapy.
Aggressive SG&A Discipline
Operating expenses are stable and highly controlled. Q2 SG&A fell a staggering $30M YoY to $55.3M, driven by cuts to inefficient direct-to-consumer (DTC) advertising. Management is proving they can scale revenue (+88% YoY) while keeping cash expenses flat to down.
Debt Burden Weighing on True Profitability
While management champions 'operating profitability, excluding stock-based compensation,' the bottom line tells a different story. Interest expense alone was $15.1M in Q2, wiping out the operating gains. With a $17.6M GAAP net loss, the company is still burning value before factoring in debt servicing costs.
Covered Prescription Mix is Stable, Not Growing
Covered prescriptions accounted for 64% of total volume in Q2 (209,000 out of 325,000). While volume is up, this percentage is completely stagnant compared to historical quarters (e.g., Q4 2025 was also ~64%). The company remains heavily reliant on cash-pay (BlinkRx) channels to clear payer friction.
Other KPIs
Accelerating improvement. Down drastically from a $75.8M loss a year ago, and halved sequentially from a $30.4M loss in Q1 2026. However, interest expense of $15.1M remains a massive drag on the bottom line.
Stable. Up slightly by $1.6M from Q1 2026 ($180.9M). The cash bleed has officially stopped at the operating level, giving the company a massive runway without the immediate threat of dilutive equity raises.
Guidance
Decelerating. Lowered from prior guidance of $320-$345 million. With $132.5M generated in H1, the new midpoint ($317.5M) implies H2 revenue of $185M. While this is sequential growth over H1, the ceiling has been distinctly lowered by management.
Accelerating efficiency. Lowered from the previous $235-$255 million range. Excludes stock-based compensation. With $112.6M spent in H1, the midpoint implies a very stable H2 run rate of ~$127M.
Key Questions
Revenue Guidance Reduction
You achieved a record Q2 with 88% YoY revenue growth and accelerating sequential prescriptions, yet you lowered the top-end of your full-year revenue guidance by $20 million. What specific headwinds or channel dynamics are you forecasting for the second half that prompted this cut?
As-Needed (PRN) Trial Economics
As you initiate the Phase 3 PRN program in Q4, how are you viewing the long-term cannibalization risk? Will a PRN label lead to patients filling fewer scripts annually compared to chronic daily maintenance?
Interest Expense Drag
While operating profitability ex-SBC is a great milestone, you are still carrying over $15M in quarterly interest expense. Do you have a timeline for when true GAAP net income or free cash flow will turn positive, allowing for organic debt paydown?